share_log

Mikra Applies to Health Canada for CELLF 2.0 NPN

Mikra Applies to Health Canada for CELLF 2.0 NPN

Mikra向加拿大衛生部申請CELLF 2.0 NPN
GlobeNewswire ·  07/08 07:00

TORONTO, July 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, reports that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") has filed a Natural Health Product License Application ("PLA") with Health Canada, seeking a Natural Product Number ("NPN") for its best-selling cellular health product CELLF 2.0.

Lifeist Wellness公司(“Lifeist”或“公司”)(TSXV:LFST)(FRANKFURT:M5B0)(OTCMKTS:LFSWF)是一家健康科技公司,利用科學和技術的進步來構建突破性的企業,以改變人類的健康狀況。公司的美國生物科學子公司Mikra Cellular Sciences Inc.(“Mikra”)已向加拿大衛生部提出自然健康產品許可申請(“PLA”),尋求其暢銷的細胞健康產品CELLF 2.0的天然產品編號(“NPN”)批准。

"We're pleased to announce that Mikra has applied to Health Canada for an NPN for CELLF 2.0," said Andrea Judge, CEO of Mikra. "Receiving this NPN will allow us to market and promote CELLF 2.0 throughout Canada, both directly and via multiple other sales channels. We look forward to successfully navigating the Health Canada application process and wish to thank our experienced advisors at KGK Science Inc. for their sound guidance throughout the preparation and drafting of our application."

Mikra的首席執行官安德烈婭·詹奈特(Andrea Judge)表示:“我們很高興宣佈Mikra已向加拿大衛生部申請CELLF 2.0的NPN。獲得此NPN將使我們能夠通過多個其他銷售渠道在加拿大市場和推廣CELLF 2.0。我們期待成功地通過衛生部的申請過程,並感謝我們在申請準備和起草期間的有經驗的KGk Science Inc.顧問爲我們提供的有益指導。”

CELLF 2.0 provides a complete adult daily dose of Pyrroloquinoline Quinone (PQQ) and Glutathione, alongside the recommended dose of bioavailable CoQ10, in a liposomal gel that is precision engineered to protect all of these key molecules from the corrosive effects of stomach acid, delivering them safely to be absorbed by the small intestine and guaranteeing that the full clinical dose becomes bioavailable. The latest published research confirms the vital role played by CELLF 2.0's key ingredients.

CELLF 2.0提供了一種完整的吡咯烷醌(PQQ)和谷胱甘肽的成人每日劑量,以及可生物利用的輔酶Q10的推薦劑量,在一個精密的脂質體凝膠中,該凝膠被精密地設計以保護所有這些關鍵分子免受胃酸的腐蝕作用,從而使它們安全地被小腸吸收,並確保全面的臨床劑量成爲生物利用。最近發佈的研究證實了CELLF 2.0的關鍵成分所起的重要作用。

In 2023 a double-blind, randomized controlled trial completed in Japan found1:

2023年,日本進行了一項雙盲、隨機對照試驗,結果如下1:

After 12 weeks, the participants showed improvements in composite memory and verbal memory... In younger adults (aged 20-40 years), PQQ improved cognitive function (cognitive flexibility, processing speed, and execution speed) after 8 weeks... Older adults (aged 41-65 years) showed improvements in complex and verbal memory after 12 weeks.

經過12周的治療,參與者在組合記憶和詞語記憶方面取得了進步……在年輕人(20-40歲)中,PQQ在8周後改善了認知功能(認知靈活性,處理速度和執行速度)……年長者(41-65歲)在12周後顯示了複雜和語言記憶的改善。

In 2023 a study conducted jointly at Canadian and Chinese research universities concluded2:

2023年,在加拿大和中國研究大學的共同研究中2證明:

This study reveals the underlying mechanism of PQQ's strong antioxidant capacity and provides evidence for PQQ as a potential agent for clinical prevention and treatment of natural aging-induced osteoporosis.

這項研究揭示了PQQ具有強抗氧化能力的潛在機制,併爲PQQ作爲治療自然老化誘導的骨質疏鬆症的潛在藥物提供了證據。

In 2023 a comprehensive research review completed at a medical university in Italy determined3:

2023年,在意大利的一所醫學大學完成了一項全面的研究3:

There is evidence of enhanced glutathione levels in elderly subjects with excellent physical and mental health status, suggesting that heightened glutathione may be a marker and even a causative factor of increased healthspan and lifespan. Such aspects, and much more including glutathione-boosting substances administrable to humans, are considered in this state-of-the-art review, which deals with glutathione and glutathione-dependent enzymes from biochemistry to gerontology, focusing attention also on lifespan/healthspan extension and successful aging; the significance of glutathione levels in aging is considered also in relation to therapeutic possibilities and supplementation strategies... Aimed at increasing glutathione and related defenses to improve health status and counteract aging processes in humans.

有證據表明,身體和精神健康狀況良好的老年人群體中,谷胱甘肽水平增強,這表明高谷胱甘肽水平可能是增加健康壽命和生命壽命的標誌甚至是原因。本綜述包含了谷胱甘肽和谷胱甘肽依賴型酶的生化和老年學研究,以及針對人類可使用的谷胱甘肽升級物質的探討;同時關注於延長壽命/健康壽命和成功老齡化,考慮了谷胱甘肽水平在衰老過程中的作用,以及在治療和補充策略方面的重要性……旨在提高谷胱甘肽和相關防禦措施,以改善人類的健康狀況並抵禦衰老過程。

CELLF 2.0 is a clinically validated formula proven to boost energy and focus on a cellular level, while protecting against the negative effects of oxidative stress. Meticulously researched, the precision-engineered formula is designed to add healthy, energetic years to your life, so you can feel better, longer. Lifeist is committed to bringing natural products backed by real science to market and looks forward to reaching many more customers in 2024.

CELLF 2.0是一種經過臨床驗證的處方,被證明可以在細胞水平上提高能量和專注力,並保護免受氧化應激的負面影響。這種精密製造的處方經過仔細的研究,旨在爲您的生活增加健康、充滿活力的歲月,讓您感覺更好、更長久。Lifeist致力於推出受真正科學支持的天然產品,並期待在2024年獲得更多的客戶。

About Lifeist Wellness Inc.

關於Lifeist Wellness Inc。

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include Mikra, a biosciences and consumer wellness company developing and selling innovative products for cellular health, and CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products.

作爲後疫情時代健康領域革命的先鋒,Lifeist利用科學和技術的進步來建立突破性的企業,改變人類健康狀況。投資組合業務單元包括Mikra,一家生物科學和消費者健康公司,開發和銷售面向細胞健康的創新產品,以及CannMart,這是一家B2B億的批發銷售分銷業務,爲加拿大省政府控制委員會提供娛樂大麻銷售,包括CannMart Labs,這是一家生產高利潤的大麻2.0產品的BHO提取設施。

Information on Lifeist and its businesses can be accessed through the links below:

Lifeist及其業務的信息可以通過以下鏈接訪問:

Contact:
Meni Morim
CEO

Brian Siegel,IRC,MBA-高級管理董事,Hayden IR,電話:(346)396-8696,ir@zedge.net
Meni Morim
首席執行官

Lifeist Wellness Inc.

Lifeist Wellness Inc。

Ph: 647-362-0390
Email: ir@lifeist.com

電話:647-362-0390
郵箱:ir@lifeist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

TSX Venture Exchange及其監管服務提供商(根據TSX Venture Exchange的政策定義)不接受對本發佈內容的充分性或準確性的責任,也沒有以任何方式批准或否認本新聞發佈的內容。

Forward Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新聞發佈含有適用證券法律法規下的“前瞻性信息”。本文所包含的非歷史性語句均提供前瞻性信息。前瞻性信息可以通過諸如“可能”、“預計”、“有望”、“應當”、“將會”、“計劃”、“預料”、“旨在”、“潛力”、“建議”、“估計”、“相信”等用語或短語來確定,亦可通過其他類似的單詞、表達方式或語法變體,或聲明某些事件或條件“可能”發生或“將會”發生的語句來確定。

The forward-looking information contained herein, including, without limitation, statements related to Mikra reaching additional customers in 2024, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, the effectiveness and benefits of CELLF 2.0 are as anticipated, customer interest in Mikra's products including CELLF 2.0 and resulting sales will be as anticipated, its expectation that the nutraceutical market will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, expectations that CELLF, CELLF 2.0, RESCUE, SERENITY, PROTECT and other new nutraceutical products to be developed by Mikra will gain market acceptance along with the expansion of the market for nutraceutical products, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: customer uptake and resulting sales of CELLF 2.0 failing to materialize as anticipated, the inability of the Company to develop Mikra's business as anticipated, unanticipated changes to current regulations that would adversely impact Mikra's business, unforeseen developments that would delay Mikra's ability to sell newly developed nutraceutical products, the risk that the expected demand for nutraceutical products in general and those of Mikra in particular does not develop as anticipated and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A filed under the Company's SEDAR+ profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

此處的前瞻性信息,包括但不限於Mikra在2024年獲得更多客戶的聲明,是在本新聞發佈日期作出的,基於管理層在發表此類聲明時認爲的合理假設,包括但不限於CELLF 2.0的效力和效益如預期,客戶對Mikra的產品,包括CELLF 2.0,感興趣,導致銷售如預期,它預計保健品市場將按目前的預期發展,保健品市場將繼續是一個價值數十億美元的高利潤市場,引入新產品和品牌將產生額外的收入,預計Mikra將開發的CELLF、CELLF 2.0、RESCUE、SERENITY、PROTECt等新的保健品將得到市場認可,同時保健品市場也將擴大等等。雖然我們認爲這些假設是合理的,基於管理層目前可獲得的信息,但沒有保證這些期望將被證明是正確的。由於前瞻性信息的某些本質特徵會產生一般或特定的固有風險和不確定性,在某些情況下,會導致預期、預測、預測、投射或結論不正確,假設可能是不正確的,目標、戰略目標和優先事項可能無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的,都可能導致前瞻性信息在本新聞發佈中的準確性與真實性不同。此類因素包括但不限於以下內容:CELLF 2.0的客戶增長和隨之而來的銷售未能如預期般出現,公司無法按預期發展Mikra的業務,當前法規發生意外變化,將對Mikra的業務造成不利影響,預計需要更長時間才能銷售新開發的保健品,預測保健品市場總體需求和Mikra在特定需求方面的產品不會如預期增長,以及與公司業務戰略的執行以及實現其所帶來的收益相關的風險。可以在Sedar +檔案下的公司當前MD&A中找到其他風險因素。請讀者注意,不要過分依賴前瞻性信息。該公司不承擔更新或修訂任何前瞻性信息的義務,除非適用法律有要求。本新聞發佈中的前瞻性陳述顯然受到此警告聲明的限制。

Source: Lifeist Wellness Inc.

資訊來源: Lifeist Wellness Inc.

1 Pyrroloquinoline quinone improves brain function in both younger and older adults

1 Pyrroloquinoline quinone improves brain function in both younger and older adults

2 Pyrroloquinoline quinone alleviates natural aging-related osteoporosis

2 Pyrroloquinoline quinone alleviates natural aging-related osteoporosis

3 Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging

3 Glutathione and glutathione-dependent enzymes: From biochemistry to gerontology and successful aging


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論